What is the NAMS Hormone Therapy Position Statement?

Updated: Oct 16, 2018
  • Author: Janice L Bacon, MD; Chief Editor: Richard Scott Lucidi, MD, FACOG  more...
  • Print
Answer

Answer

Over the years, the number of prescriptions for hormone therapy has reflected scientific findings. In the 1970s, the number of prescriptions increased to approximately 30 million per year. This practice was likely due to data suggesting the cardioprotective effects of hormone therapy.

In the 1980s, reports of increased rates of endometrial cancer with unopposed estrogen lead to a decrease in annual prescriptions to about 15 million. Then, the addition of progestogen for endometrial protection renewed interest in hormone therapy, and prescriptions again increased.

Between 1995 and 2002, annual prescriptions peaked at about 91 million. Termination of the estrogen-progestin arm of the WHI in July 2002 and release of the HERS II data received considerable media attention and raised serious questions about the safety of hormone therapy in postmenopausal women. Many women stopped taking hormones and began to seek out alternative therapies. Prescriptions for hormone treatment immediately decreased. Of note, prescriptions for vaginal preparations did not change during this time. [49]

The NAMS Hormone Therapy Position Statement in 2012, updated in 2017 with evaluation of new literature and assessment of long-term randomized clinical trials, as well as observational studies reaffirms the use of HT with thorough discussion of risks and benefits and individualization of therapy. Re-evaluation of these risks and benefits over time for each patient allows modifications and/ or continuation of the therapies. [113]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!